循环肿瘤DNA在结直肠癌中的应用

伍龙; 吴欢; 黄飞; 李晓云; 甄运寰; 李海洋

doi:10.16766/j.cnki.issn.1674-4152.003404

循环肿瘤DNA在结直肠癌中的应用

doi: 10.16766/j.cnki.issn.1674-4152.003404

伍龙¹,
吴欢²,
黄飞¹,
李晓云¹,
甄运寰¹,
李海洋^3, ,

1.
贵州医科大学附属医院肛肠外科，贵州贵阳 550004
2.
贵州医科大学附属医院感染科
3.
贵州医科大学附属医院肝胆外科

基金项目:

国家自然科学基金地区基金项目 82060440

贵州省卫生健康委科学技术基金项目 gzwkj2023-042

详细信息

通讯作者:
李海洋，E-mail：lihaiyang@gmc.edu.cn

中图分类号: R735.35 R735.37
计量
- 文章访问数: 99
- HTML全文浏览量: 47
- PDF下载量: 5
- 被引次数: 0
出版历程
- 收稿日期: 2023-06-27
- 网络出版日期: 2024-05-27

Circulating tumor DNA in colorectal cancer

1.
Department of Anus and Intestine Surgery, the Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550004, China

摘要

摘要: 结直肠癌是我国常见的癌症类型之一，也是世界第二大死因。随着诊断技术的发展和包括手术和化疗在内的治疗方法的进步，其预后得到了极大的改善，但是仍有一定比例的患者在接受根治性治疗后出现复发。循环肿瘤DNA(ctDNA)是来自肿瘤细胞的循环游离DNA(cfDNA)片段，是一种新型的生物标志物，可以用于监测结直肠癌患者的放化疗效果和术后复发情况。与传统的生物标志物相比，ctDNA具有更高的特异度和灵敏度，并且可以在患者的血清中稳定存在。通过检测ctDNA的水平可以对患者的病情进行更加准确的评估，并根据检测结果制定更加个性化的治疗方案。在结直肠癌的诊疗过程中，ctDNA具有较高的特异度和灵敏度，通过检测患者的血清ctDNA水平，可以较早期判断患者是否可能患有结直肠癌。同时，通过比较患者治疗前后的血清ctDNA水平变化，可以评估患者的治疗效果。在结直肠癌的随访中，ctDNA同样具有很高的特异度和灵敏度，通过检测患者的血清ctDNA水平，可以有效地判断患者的复发情况。若患者血清ctDNA水平持续升高，则表明患者可能出现了复发，需要及时进行进一步的检查和干预。总之，ctDNA是一种新型的生物标志物，具有较高的特异度和灵敏度，可以用于监测结直肠癌患者的放化疗效果和术后复发情况，目前被认为是液体活检中的新型生物标志物之一，可作为放化疗效果评估、术后复发监测等的生物标志物。本文综述了ctDNA的特征及其在结直肠癌诊断、治疗和随访中的应用。
- 结直肠癌 /
- 循环肿瘤DNA /
- 应用
Abstract: Colorectal cancer is a prevalent form of cancer in China and is the second leading cause of death worldwide. The prognosis of the disease has greatly improved with the development of diagnostic techniques and advances in therapeutic methods, including surgery and chemotherapy. However, a certain percentage of patients still experience recurrence after radical treatment circulating tumor DNA (ctDNA) is a cell-free circulating DNA (cfDNA) fragment derived from tumor cells. It is a novel biomarker that can be used to monitor the efficacy of radiotherapy and postoperative recurrence in colorectal cancer patients. Compared to traditional biomarkers, the ctDNA has higher specificity and sensitivity and can be stably present in patients ' serum. Detecting ctDNA levels allows for a more accurate assessment of the patient ' s condition and the formulation of a personalized treatment plan based on test results. The use of ctDNA in the diagnosis and treatment of colorectal cancer offers high specificity and sensitivity. By detecting the level of ctDNA in a patient ' s serum, it is possible determined whether they may have colorectal cancer at an early stage. Meanwhile, by comparing the changes in serum ctDNA levels before and after treatment, the therapeutic effect of patients can be evaluated. In colorectal cancer follow-up, ctDNA has high specificity and sensitivity. By detecting the patient ' s serum ctDNA level, recurrence can be effectively determined. If the serum ctDNA level of the patient continues to increase, it suggests that the patient may have relapsed and requires prompt examination and intervention. In conclusion, ctDNA is a promising biomarker with high specificity and sensitivity. It can be used to monitor the effectiveness of radiotherapy and detect postoperative recurrence in patients with colorectal cancer. It is currently considered one of the novel biomarkers in liquid biopsy. It can be used to assess radiotherapy effect and monitor postoperative recurrence. This makes it a valuable biomarker. This paper presents a review of the characteristics of ctDNA and its applications in the diagnosis, treatment and follow-up of colorectal cancer.
- Colorectal cancer /
- Circulating tumor DNA /
- Application

HTML全文

参考文献(44)

[1]	郑荣寿, 张思维, 孙可欣, 等. 2016年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2023, 45(3): 212-220. doi: 10.3760/cma.j.cn112152-20220922-00647 ZHENG R S, ZHANG S W, SUN K X, et al. Cancer statistics in China, 2016[J]. Chinese Journal of Oncology, 2023, 45(3): 212-220. doi: 10.3760/cma.j.cn112152-20220922-00647
[2]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[3]	XIA C, DONG X, LI H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J(Engl), 2022, 135(5): 584-590.
[4]	CHEN Y, WANG Z, ZHAO G, et al. Performance of a novel blood-based early colorectal cancer screening assay in remaining serum after the blood biochemical test [J]. Dis Markers, 2019, 2019: 5232780. DOI: 10.1155/2019/5232780.
[5]	TIE J, COHEN J D, WANG Y, et al. Circulating tumor dna analyses as markers of recurrence risk and benefit of adjuvant therapy for stage Ⅲ colon cancer[J]. JAMA Oncol, 2019, 5(12): 1710-1717. doi: 10.1001/jamaoncol.2019.3616
[6]	GAO Q, LIN Y P, LI B S, et al. Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies[J]. Ann Oncol, 2023, 34(5): 486-495. doi: 10.1016/j.annonc.2023.02.010
[7]	TARAZONA N, GIMENO-VALIENTE F, GAMBARDELLA V, et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer[J]. Ann Oncol, 2019, 30(11): 1804-1812. doi: 10.1093/annonc/mdz390
[8]	MANDEL P, METAIS P. Nuclear acids in human blood plasma[J]. C R Seances Soc Biol Fil, 1948, 142(3-4): 241-243.
[9]	OSUMI H, SHINOZAKI E, TAKEDA Y, et al. Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer[J]. Cancer Med, 2019, 8(1): 408-417. doi: 10.1002/cam4.1913
[10]	曾凯, 许利剑. 外泌体源性miRNA在消化道肿瘤中的研究进展[J]. 医学研究生学报, 2020, 33(1): 108-112. https://www.cnki.com.cn/Article/CJFDTOTAL-JLYB202001021.htm ZENG K, XU L J. Research progress of exosome-derived microRNA in gastrointestinal tumors[J]. Journal of Medical Research & Combat Trauma Care, 2020, 33(1): 108-112. https://www.cnki.com.cn/Article/CJFDTOTAL-JLYB202001021.htm
[11]	MESQUITA A, COSTA J L, SCHMITT F. Utility of circulating tumor DNA in different clinical scenarios of breast cancer[J]. Cancers(Basel), 2020, 12(12): 3797. DOI: 10.3390/cancers12123797.
[12]	SUN Y, LI M, REN S, et al. Exploring genetic alterations in circulating tumor DNA from cerebrospinal fluid of pediatric medulloblastoma[J]. Sci Rep, 2021, 11(1): 5638. DOI: 10.1038/s41598-021-85178-6.
[13]	PROSKURINA A S, GVOZDEVA T S, POTTER E A, et al. Five-year disease-free survival among stage Ⅱ-Ⅳ breast cancer patients receiving FAC and AC chemotherapy in phase Ⅱ clinical trials of Panagen[J]. BMC Cancer, 2016, 16: 651. DOI: 10.1186/s12885-016-2711-5.
[14]	LEAL A, VAN GRIEKEN N C T, PALSGROVE D N, et al. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer[J]. Nat Commun, 2020, 11(1): 525. DOI: 10.1038/s41467-020-14310-3.
[15]	HENRIKSEN T V, REINERT T, CHRISTENSEN E, et al. The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA[J]. Mol Oncol, 2020, 14(8): 1670-1679. doi: 10.1002/1878-0261.12729
[16]	ROTH S, WERNSDORF S R, LIESZ A. The role of circulating cell-free DNA as an inflammatory mediator after stroke[J]. Semin Immunopathol, 2023, 45(3): 411-425. doi: 10.1007/s00281-023-00993-5
[17]	KHUSH K K. Clinical utility of donor-derived cell-free DNA testing in cardiac transplantation[J]. J Heart Lung Transplant, 2021, 40(6): 397-404. doi: 10.1016/j.healun.2021.01.1564
[18]	BREITBACH S, TUG S, SIMON P. Circulating cell-free DNA: an up-coming molecular marker in exercise physiology[J]. Sports Med, 2021, 42(7): 565-586.
[19]	蒋晓芬, 邵传锋, 张浩, 等. 循环肿瘤细胞联合癌胚抗原检测在Ⅰ、Ⅱ期结直肠癌诊断中的应用研究[J]. 中华全科医学, 2018, 16(10): 1653-1655. doi: 10.16766/j.cnki.issn.1674-4152.000450 JIANG X F, SHAO C F, ZHANG H, et al. Application of circulating tumor cells combined with carcinoembryonic antigen in the diagnosis of stage Ⅰ and Ⅱ colorectal cancer[J]. Chinese Journal of General Practice, 2018, 16(10): 1653-1655. doi: 10.16766/j.cnki.issn.1674-4152.000450
[20]	YANG Y C, WANG D, JIN L, et al. Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients[J]. Biosci Rep, 2018, 38(4): BSR20180322. DOI: 10.1042/BSR20180322.
[21]	WANG X, SHI X Q, ZENG P W, et al. Circulating cell free DNA as the diagnostic marker for colorectal cancer: a systematic review and meta-analysis[J]. Oncotarget, 2018, 9(36): 24514-24524. doi: 10.18632/oncotarget.25314
[22]	XIE L, JIANG X, LI Q, et al. Diagnostic value of methylated Septin9 for colorectal cancer detection[J]. Front Oncol, 2018, 8: 247. DOI: 10.3389/fonc.2018.00247.
[23]	邵书先, 沈忠, 张秀峰, 等. 粪便多基因联合检测在结直肠癌早期筛查中的应用[J]. 中华全科医学, 2020, 18(11): 1819-1822. doi: 10.16766/j.cnki.issn.1674-4152.001627 SHAO S X, SHEN Z, ZHANG X F, et al. Application of multiple-gene stool DNA test in screening for early colorectal cancer[J]. Chinese Journal of General Practice, 2020, 18(11): 1819-1822. doi: 10.16766/j.cnki.issn.1674-4152.001627
[24]	LUO H, ZHAO Q, WEI W, et al. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer[J]. Sci Transl Med, 2020, 12(524): eaax7533. DOI: 10.1126/scitranslmed.aax7533.
[25]	WILLIS J, LEFTEROVA M I, ARTYOMENKO A, et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel[J]. Clin Cancer Res, 2019, 25(23): 7035-7045. doi: 10.1158/1078-0432.CCR-19-1324
[26]	NORMANNO N, ESPOSITO ABATE R, LAMBIASE M, et al. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial[J]. Ann Oncol, 2018, 29(1): 112-118. doi: 10.1093/annonc/mdx417
[27]	闫巍, 张能维, 徐智, 等. 结直肠癌患者手术前后循环DNA水平的变化及其意义[J]. 中国普通外科杂志, 2013, 22(12): 1627-1630. doi: 10.7659/j.issn.1005-6947.2013.12.021 YAN W, ZHANG N W, XU Z, et al. Alteration of pre- and postoperative circulating DNA level in colorectal cancer patients and its significance[J]. China Journal of General Surgery, 2013, 22(12): 1627-1630. doi: 10.7659/j.issn.1005-6947.2013.12.021
[28]	翟晓璐, 王妍, 王斐, 等. 循环肿瘤DNA检测对Ⅱ期结直肠癌术后患者预后的预测价值[J]. 现代肿瘤医学, 2023, 31(21): 3968-3972. doi: 10.3969/j.issn.1672-4992.2023.21.012 ZHAI X L, WANG Y, WANG F, et al. Predictive value of circulating tumor DNA detection on prognosis of patients with stage Ⅱ colorectal cancer after operation[J]. Journal of Modern Oncology, 2023, 31(21): 3968-3972. doi: 10.3969/j.issn.1672-4992.2023.21.012
[29]	廖亮亮. ctDNA在结直肠癌诊治过程中临床意义的初步探讨[D]. 长春: 吉林大学, 2023. LIAO L L. Clinical significance of ctDNA in the diagnosis and treatment of colorectal cancer: a preliminary study[D]. Changchun: Jilin University, 2023.
[30]	MISALE S, YAEGER R, HOBOR S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer[J]. Nature, 2012, 486(7404): 532-536. doi: 10.1038/nature11156
[31]	SARTORE-BIANCHI A, TRUSOLINO L, MARTINO C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2016, 17(6): 738-746. doi: 10.1016/S1470-2045(16)00150-9
[32]	RIMASSA L, BOZZARELLI S, PIETRANTONIO F, et al. Phase Ⅱ study of tivantinib and cetuximab in patients with kras wild- type metastatic colorectal cancer with acquired resistance to EGFR inhibitors and emergence of MET overexpression: lesson learned for future trials with EGFR/MET dual inhibition[J]. Clin Colorectal Cancer, 2019, 18(2): 125-132. e2. doi: 10.1016/j.clcc.2019.02.004
[33]	TOSI F, SARTORE-BIANCHI A, LONARDI S, et al. Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer[J]. Clin Colorectal Cancer, 2020, 19(4): 256-262. e2. doi: 10.1016/j.clcc.2020.06.009
[34]	CHEN X, QIU T, ZHU Y, et al. A single-arm, phase Ⅱ study of apatinib in refractory metastatic colorectal cancer[J]. Oncologist, 2019, 24(7): 883-e407. DOI: 10.1634/theoncologist.2019-0164.
[35]	WANG Y, LI L, COHEN J D, et al. Prognostic potential of circulating tumor DNA measurement in postoperative surveillance of nonmetastatic colorectal cancer[J]. JAMA Oncol, 2019, 5(8): 1118-1123. doi: 10.1001/jamaoncol.2019.0512
[36]	REINERT T, HENRIKSEN T V, CHRISTENSEN E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages Ⅰ to Ⅲ colorectal cancer [J]. JAMA Oncol, 2019, 5(8): 1124-1131. doi: 10.1001/jamaoncol.2019.0528
[37]	TIE J, WANG Y, TOMASETTI C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage Ⅱ colon cancer [J]. Sci Transl Med, 2016, 8(346): 346ra392. DOI: 10.1126/scitranslmed.aaf6219.
[38]	闫星, 刘山梅, 刘长宏. 不同体液标本活检在肺癌微小残留疾病监测中的应用最新进展[J]. 中国全科医学, 2023, 26(3): 280-286. doi: 10.12114/j.issn.1007-9572.2022.0641 YAN X, LIU S M, LIU C H. Different body fluid biopsies for detecting minimal residual disease in lung cancer: a review of the latest advances[J]. Chinese General Practice, 2023, 26(3): 280-286. doi: 10.12114/j.issn.1007-9572.2022.0641
[39]	FAULKNER L G, HOWELLS L M, PEPPER C, et al. The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis [J]. Br J Cancer, 2023, 128(2): 297-309. doi: 10.1038/s41416-022-02017-9
[40]	CHEN G, PENG J, XIAO Q, et al. Postoperative circulating tumor DNA as markers of recurrence risk in stages Ⅱ to Ⅲ colorectal cancer [J]. J Hematol Oncol, 2021, 14(1): 80. doi: 10.1186/s13045-021-01089-z
[41]	王舒艺, 熊斌, 杨朝纲. 循环肿瘤细胞检测在胃肠道肿瘤诊疗中的应用中国专家共识(2023版) [J]. 实用肿瘤杂志, 2023, 38(6): 497-504. https://www.cnki.com.cn/Article/CJFDTOTAL-SYZZ202306001.htm WANG S Y, XIONG B, YANG C G. Chinese expert consensus on application of circulating tumor cell detection in diagnosis and treatment of gastrointestinal neoplasms(2023 edition)[J]. Journal of Practical Oncology, 2023, 38(6): 497-504. https://www.cnki.com.cn/Article/CJFDTOTAL-SYZZ202306001.htm
[42]	中华医学会肿瘤学分会, 国家卫生健康委员会医政司. 中国结直肠癌诊疗规范(2023版) [J]. 协和医学杂志, 2023, 14(4): 706-733. https://www.cnki.com.cn/Article/CJFDTOTAL-XHYX202304006.htm Chinese Society of Oncology Chinese Medical Association, Hospital Authority of National Health Commission of the People ' s Republic of China. Chinese protocol of diagnosis and treatment of colorectal cancer (2023 edition)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 706-733. D https://www.cnki.com.cn/Article/CJFDTOTAL-XHYX202304006.htm
[43]	NCCN. NCCN clinical practice guidelines in oncology-colon cancer [M/OL]. [2023-11-16]. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
[44]	NCCN. NCCN clinical practice guidelines in oncology-rectal cancer [M/OL]. [2023-11-16]. https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf.